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ABSTRACT 
Background: Pressure injuries are a significant clinical and economic issue, affecting both 
patients and the health care system. Many pressure injuries in hospitals are facility acquired, 
and are largely preventable. Despite growing evidence and directives for pressure injury 
prevention, implementation of preventative strategies is suboptimal, and pressure injuries 
remain a serious problem in hospitals.  
Objectives: This study will test the effectiveness and cost-effectiveness of a patient-centred 
pressure injury prevention care bundle on the development of hospital acquired pressure 
injury in at-risk patients. 
Design: This is a multi-site, parallel group cluster randomised trial. The hospital is the unit of 
randomisation. 
Methods: Adult medical and surgical patients admitted to the study wards of eight hospitals 
who are (a) deemed to be at risk of pressure injury (i.e. have reduced mobility), (b) expected 
to stay in hospital for ≥48 hours, (c) admitted to hospital in the past 36 hours; and (d) able to 
provide informed consent will be eligible to participate. Consenting patients will receive 
either the pressure injury prevention care bundle or standard care. The care bundle contains 
three main messages: 1) keep moving; 2) look after your skin; and 3) eat a healthy diet. 
Nurses will receive education about the intervention. Patients will exit the study upon 
development of a pressure injury, hospital discharge or 28 days, whichever comes first; 
transfer to another hospital or transfer to critical care and mechanically ventilated. The 
primary outcome is incidence of hospital acquired pressure injury. Secondary outcomes are 
pressure injury stage, patient participation in care and health care costs. A health economic 
sub-study and a process evaluation will be undertaken alongside the trial. Data will be 
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analysed at the cluster (hospital) and patient level. Estimates of hospital acquired pressure 
injury incidence in each group, group differences and 95% CI and p values will be reported.  
Discussion: To our knowledge, this is the first trial of an intervention to incorporate a number 
of pressure injury prevention strategies into a care bundle focusing on patient participation 
and nurse-patient partnership. The results of this study will provide important information on 
the effectiveness and cost-effectiveness of this intervention in preventing pressure injuries in 
at-risk patients. If the results confirm the utility of the developed care bundle, it could have a 
significant impact on clinical practice worldwide. 
Trial registration: This trial is registered with the Australian New Zealand Clinical Trials 
Registry, ACTRN12613001343796. 
 
What is already known about the topic? 
• Pressure injury is a significant clinical and economic issue. 
• Most hospital acquired pressure injuries are preventable. 
• Strategies to prevent pressure injuries must be complex and multidimensional. 
What this paper adds 
• This paper proposes a protocol for a complex intervention for pressure injury 
prevention, i.e. a pressure injury prevention care bundle. 
• The proposed care bundle includes three main messages: (1) keep moving; (2) look 
after your skin; and (3) eat a healthy diet. 
• The care bundle incorporates patient participation in care and encourages nurse and 
patient partnership.  
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BACKGROUND 
A pressure injury (PI), also known as pressure ulcer, is defined as “localised injury to the skin 
and/or underlying tissue usually over a bony prominence, as a result of pressure, or pressure 
in combination with shear” (European Pressure Ulcer Advisory Panel et al., 2014). PIs are a 
major problem in hospitals, affecting approximately 10 – 30% of patients worldwide, 
depending on the country, setting, patient population and presence of pressure injury 
prevention (PIP) strategies (Banks et al., 2010, Gunningberg et al., 2013, Igarashi et al., 2013, 
James et al., 2010). The majority of PIs in the clinical setting are hospital acquired pressure 
injuries (HAPI) (Gallagher et al., 2008, Gunningberg et al., 2011, Lyder et al., 2012). Two 
European studies of nearly 2000 hospitalised patients reported PI prevalence between 15 – 
19%, and 77 – 78% of these were HAPI (Gallagher et al., 2008, Gunningberg et al., 2011). In 
Australia, the incidence of HAPI is 7.4 – 17.4% (Mulligan et al., 2011). 
PIs result in significant physical, social and physiological problems for patients, including 
pain, wound exudate and odour, decreased mobility and independence, poor body image and 
emotional issues (Gorecki et al., 2009, Gorecki et al., 2011, Latimer et al., 2014).  They also 
place a large burden on the health care system, by increasing length of stay (Graves et al., 
2005) and hospital costs (Graves and Zheng, 2014). In fact, a recent estimate of the total cost 
of PI in public and private hospitals in Australia in 2010-11 was US$1.64 billion (±US$1.05 
billion) (Graves and Zheng, 2014). PI treatment costs are estimated to represent 1.9% of all 
public hospital expenditure in Australia (Nguyen et al., 2015). Considering the significant 
negative outcomes for both patients and hospitals, PIP is of high importance. 
It is recognised that the majority of PI, particularly HAPI, are preventable (Australian 
Commission on Safety and Quality in Health Care, 2011, Ayello and Lyder, 2008, VanGilder 
et al., 2009). In 2008, the US Centres for Medicare and Medicaid Services ceased 
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reimbursing facilities for HAPIs, considering them “never events”, that is, preventable events 
that should never occur (Centers for Medicare and Medicaid Services 2007). Similarly, in the 
UK, facilities now incur financial penalties for failing to meet PIP goals, or receive financial 
incentives if goals are achieved (Department of Health, 2012). In Australia, Queensland 
public hospitals are fined AU$30,000 and AU$50,000 for stage III and IV HAPI, respectively 
(Queensland Government and Department of Health, 2014). Preventing PI is one of the 
Australian National Safety and Quality Health Service Standards, which are used to assess 
performance and accreditation of Australian health care facilities (Australian Commission on 
Safety and Quality in Health Care, 2011). The importance of PIP is also reflected in 
international PI guidelines (European Pressure Ulcer Advisory Panel et al., 2014). Due to the 
number of complex and inter-related risk factors for PI, preventative interventions must be 
complex and multifaceted (Coleman et al., 2013). Core PIP strategies include: encouraging 
mobility and appropriate support surfaces; good skin care; and nutritional assessment and 
intervention if required (European Pressure Ulcer Advisory Panel et al., 2014).  
The evidence for improvements in HAPI rates with multifaceted PIP interventions is limited 
to quality improvement projects with a lack of large-scale RCTs. However, systematic 
reviews and theory suggest that a combination of quality improvement intervention strategies 
may reduce the incidence of PI in the hospital setting (Padula et al., 2014, Soban et al., 2011, 
Sullivan and Schoelles, 2013). Several core elements are consistent across studies, including 
staff education and information sharing, leadership, performance monitoring, and PI-specific 
interventions such as protocols, guidelines and risk assessment (Padula et al., 2014, Soban et 
al., 2011, Sullivan and Schoelles, 2013), emphasising the value of multifaceted interventions. 
One systematic review highlighted a need for further understanding around implementation, 
causal pathways and the role of context in PIP interventions (Soban et al., 2011), hence the 
importance of conducting definitive trials with adequate piloting and process evaluation. 
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A care bundle is a structured group of interventions based on clinical practice guidelines that 
improve processes of care, encourage compliance to guidelines, and have been shown to 
improve patient outcomes (Institute for Healthcare Improvement, 2014, Rello et al., 2011). 
One US group developed an 8-item PIP care bundle that included skin care, turning and 
nutritional assessment, directed at nursing staff, and although their annual PI prevalence data 
showed trends towards improvements in PI prevalence, no formal analysis was undertaken 
(Baldelli and Paciella, 2008). A cluster randomised trial (c-RT) in the Netherlands found that 
a patient safety care bundle was effective in reducing adverse events, specifically PIs, urinary 
tract infections and falls among hospital and nursing home patients (van Gaal et al., 2011). 
The study employed a multifaceted implementation strategy using staff education, patient 
involvement and feedback on processes and outcomes to simultaneously implement multiple 
best practice guidelines (i.e. for each adverse event) in study wards (van Gaal et al., 2011). 
To date, care bundles have mostly focused on guiding clinicians in their practice, yet 
evidence suggests involvement of patients and their families working alongside clinicians 
could be a major driver in the use of care bundles (Coulter, 2006, van Gaal et al., 2011). 
Patient participation in their health care has been shown to reduce adverse events and 
improve patient safety (Weingart et al., 2011) and result in improved health outcomes 
(Arnetz et al., 2010, Dwamena et al., 2012). National and international groups such as the 
Australian Commission on Safety and Quality in Health Care (2011), US Joint Commission 
on Accreditation in Healthcare Organizations (2006) and the World Health Organisation 
(2007) advocate for consumer participation in health care. Importantly, “Partnering with 
consumers” is one of the 2011 Australian Safety and Quality Health Service Standards, and is 
expected to be applied in conjunction with the standard “Preventing and Managing Pressure 
Injuries” (Australian Commission on Safety and Quality in Health Care, 2011). Recent 
research on patient and health professional views about patient participation suggests that 
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many interventions work optimally when both the health professional and patient have a role 
in the initiative (Davis et al., 2012). However, rigorous studies that have examined the impact 
of patient-clinician partnerships on patient outcomes in the acute care setting are lacking 
(Coulter, 2006). 
In summary, PIs contribute to significant burden for patients and the health care system. As 
many HAPI are considered preventable, strategies for PIP warrant special consideration, yet 
research suggests they are poorly implemented. A patient-centred PIP care bundle may be an 
effective approach to PIP, and is consistent with evidence on the benefits of care bundles and 
mandates for patient participation in care. Patients, who have a vested interest in PIP, may be 
an untapped resource to prompt timely use of PIP strategies.  
Consequently, an innovative PIP strategy was developed (Chaboyer and Gillespie, 2014, 
Gillespie et al., 2014) that is intended to optimise efficacy and sustainability, namely a care 
bundle that incorporates patient participation in care, easy access to PIP information and 
nursing staff engagement. This paper reports the protocol currently being used to test this 
care bundle, namely the INTACT trial (INTroducing A Care bundle To prevent pressure 
injury in at-risk patients).  
Aims and hypotheses 
This study aims to provide rigorous evidence regarding the effect of a PIP care bundle on the 
development of HAPI in patients at risk of PI.  
Primary Hypothesis: The incidence of HAPI in “at risk” hospitalised patients who receive a 
PIP care bundle will be lower than that in at risk hospitalised patients receiving standard care.   
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Secondary Hypotheses: The intervention group will have better outcomes than the standard 
care group in terms of: (a) PI stage, i.e., depth of tissue damage; (b) patient participation in 
care; and (c) healthcare costs.  
All hypotheses apply to both the cluster level and the patient level (see data analysis). 
METHODS/DESIGN 
Study design 
This study is a multi-site, parallel group cluster randomised trial (c-RT). The unit of 
randomisation will be hospitals to prevent contamination between groups. Wards cannot be 
randomised as there is substantial patient movement between wards. Patients will receive 
either the intervention or standard care. The primary outcome is incidence of HAPI, and 
secondary outcomes are PI stage, patient participation in care and health care costs. Patients 
will exit the study upon: reaching study day 28; development of a PI; hospital discharge; 
transfer to another hospital; or transfer to critical care and requiring mechanical ventilation. 
An economic sub-study will evaluate the cost effectiveness of the intervention compared to 
routine care. A project manager (based at a university) will coordinate overall management of 
the project. Their role will entail assisting with the development of the database, coordinating 
ethics applications, overseeing and/or delivering research assistant training, site monitoring 
both during start up and during the trial, assessment of data quality.  At each site, a study 
investigator who is a senior researcher and four separate groups of research assistants will be 
involved: (1) to recruit patients; (2) to deliver the intervention; (3) to collect data for the 
economic evaluation; and (4) to collect daily data to assess the outcomes (incidence of 
HAPI). The trial has been approved by the Queensland Health Human Research Ethics 
Committee (reference number HREC/13/QGC/192), and by five hospitals and one university. 
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The trial is registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN12613001343796) and is funded by the National Health and Medical Research 
Council (APP1058963). 
Setting 
To be eligible for the study, hospitals must (a) be metropolitan referral hospitals that cater for 
diverse patient adult populations and case-mix groups; (b) offer acute medical and surgical 
and rehabilitative services; and (c) have 200 or more beds. All patients from wards except 
day-surgery, critical care, emergency, maternity, paediatrics, mental health and dialysis units 
will be eligible to participate.  There will be 5-15 wards able to participate at each site, which 
ensures diverse geographical, unit size and sub specialty representation. Methodological and 
pragmatic issues were considered in determining the number of sites. A total of eight acute 
care hospitals in Queensland, New South Wales and Victoria, Australia, have agreed to 
participate.  
Randomisation  
Generation of the allocation sequence and random 1:1 block allocation of hospitals to 
intervention or control group will be undertaken using a central randomisation service not 
involved in the study in any way. Hospitals will be stratified by the current HAPI rates as 
reported in each hospital. Allocation based on clusters will be concealed until the intervention 
is assigned.  A statistician, not involved in recruitment and blinded to groups (treatment/ 
control) will generate a series of random number lists for 4, 6, 8, 10 and 12 wards. The lists 
will then be sent to recruiters, who will determine the number of wards they will recruit from 
and the order in which wards will be approached. Hospitals will be informed of which arm of 
the study they are randomised to on completion of data collection. The chief investigators and 
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interventionists will not be blinded to group allocation but the recruiters, outcome assessors 
and analysts will be blinded. These latter research assistants will be informed about group 
allocation at the end of the data collection. 
Participants 
A consecutive sample of patients in the study wards who meet all inclusion and no exclusion 
criteria will be recruited into the sample.  
Inclusion criteria: (i) adults admitted to a study ward; (ii) expected hospital length of stay of 
≥48 hours; (iii) at risk of PI as measured by limited mobility (i.e. requiring physical or 
mechanical assistance to reposition or ambulate); (iv) able to read English; and (v) able to 
provide informed consent.  
Exclusion criteria: (i) previous participation in this trial; (ii) admitted to the hospital for >36 
hours prior to recruitment; and (iii) palliative or dying patients. 
Recruitment 
We plan to commence recruiting at one site, to test procedures and other processes before 
recruitment commences at other sites. For each site, a computer-generated ward 
randomisation schedule will be developed and used to determine the order of approaching 
wards for recruitment of patients. This is to ensure that all wards in a particular institution are 
fairly represented. The number of wards approached each week will depend on recruitment 
rates at that site. The recruiters, from Monday to Friday, will screen eligibility of all patients 
admitted to study wards using a screening tool reflecting the inclusion and exclusion criteria. 
Patients will only be screened once. The nurse unit manager will ask potential participants if 
they are willing to be approached about this study, and if patients agree, they will be 
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consecutively approached by recruiters according to the ward randomisation schedule. Verbal 
and written information about the study will be provided before seeking consent from the 
patient. Recruitment will continue until 200 patients have been recruited at each site. The trial 
period (i.e. time from first recruitment to final completion) is expected to be nine months. 
Figure 1 shows anticipated participant flow through the study. 
Sample Size 
The incidence of HAPI in Australian hospitals ranges from 7.4% – 17.4% (Mulligan et al., 
2011). A Cochrane review on support surfaces reporting a meta-analysis of five studies 
indicated a reduction in PI in at risk patients (RR 0.40, 95% CI 0.21 – 0.74) (McInnes et al., 
2012). In our sample size estimate we have taken a conservative approach of incidence of 
10% HAPI (control) with an expected reduction of 50% or an absolute reduction of 5% (from 
10% to 5%) in the intervention group and an intra-class correlation  of 0.001, the actual intra-
class correlation in another c-RT of a PIP strategy (Moore et al., 2011). To obtain 90% power 
with a two-sided α level of 0.05, 8 hospitals with 169 patients per hospital are required 
(PASS – Power Analysis and Sample Size system, NCSS, Utah). Thus, the total sample 
required will be 1,352. Data from our pilot study indicated an attrition rate of just over 10%, 
hence additional patients will be recruited for a total sample of 1,600 (n = 200 per site). 
Intervention 
The intervention is a PIP care bundle aimed at both the individual (patient) and the cluster 
(hospital). It includes three main messages to promote patient participation in PIP care: (1) 
keep moving; (2) look after your skin; and (3) eat a healthy diet, which will be delivered to 
patients through a brochure, poster and DVD. Nurses will also receive training on 
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encouraging patients to engage in PIP self-care activities. Table 1 contains details of the 
intervention components and materials.  
The PIP care bundle is based on the Institute of Healthcare Improvement recommendations 
that care bundles should be evidence based and straightforward, encompassing 3-5 items 
(Institute for Healthcare Improvement, 2014). The intervention will be delivered by dedicated 
health professionals (predominantly registered nurses) with a specific interest in wound care 
to both patients and nurses (patient and cluster level). Implementing the intervention will 
involve: (a) one-to-one patient training including watching a 5 min DVD; (b) an information 
brochure on PI; (c) poster reminders; and (d) training of nursing staff to promote partnering 
with patients in PIP care and the care bundle. Interventionists will deliver the PIP care bundle 
to patients shortly after recruitment and will provide both patient education and nurse training 
throughout the study. Thus the intervention is patient-centred and reflects partnership 
between patients and nurses in the delivery of care. The intervention was previously 
developed and piloted in an acute tertiary hospital setting (Chaboyer and Gillespie, 2014, 
Gillespie et al., 2014). Awareness of the INTACT trial will be raised through a range of 
strategies such as hospital newsletters, e-mails and forums. A trial-specific education 
programme targeting all nurses in study wards will be implemented to ensure clinical staff 
understand and support the study. A run-in period of two months will include formal group 
inservices and informal discussions with staff to ensure those at intervention sites understand 
the intervention and engage in partnering with patients in PIP strategies, and those at control 
sites are aware of the study. This training will commence prior to data collection and will 
continue as deemed necessary throughout recruitment depending on ward staff turnover. 
Ideally, all nurses on study wards will receive the training at least once. The study 
investigator at each site will be responsible for organising training at that site.  
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Standard care 
For the duration of the trial, patients in the control group hospitals will receive the standard 
care provided for PIP on the particular ward. It is likely that standard care may vary from 
hospital to hospital and even between wards; consequently, we will document ‘standard care’ 
at each recruiting site. Patients in intervention group hospitals will also receive standard PIP 
care along with the intervention.  
Blinding 
Selection bias is a potential issue when undertaking cluster trials, especially when individual 
participants are recruited (Giraudeau and Ravaud, 2009). In order to minimise this potential 
bias, three strategies will be employed. Firstly, as described previously, recruiters will use a 
randomly generated ward list to determine the order by which they will approach wards 
during recruitment. Secondly, recruiters will not be the same individuals as those delivering 
the intervention. Finally, we will blind the recruiters to the actual intervention. The patient 
information and consent forms only state we will be examining various PIP strategies and in 
training recruiters will also be told this. Recruiters at each site will also be trained at their 
own hospital only. Full blinding in this study is difficult due to the study design (i.e. patients 
participating in their care) and the need for informed consent. However recruiters, nursing 
staff and patients will only be told broad details of their arm of the study, for example that the 
study involves documenting PI and various strategies for PIP, and will be unaware that the 
study is a c-RT. All research assistant groups (recruiters, interventionists and outcome 
assessors) will be blinded to study design and hypotheses, and will be trained separately to 
avoid the intervention being known to all groups. Outcome assessors will be blinded to group 
allocation and will be assigned to one hospital only. Success of outcome assessor blinding 
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will be assessed at the end of the study using the James Blinding Index (James et al., 1996). 
Finally, data analysts will be blinded to group allocation. 
Research assistant training and treatment fidelity 
All research assistants will undergo separate and group specific onsite training tailored to 
their role to ensure consistency across all sites. All research assistants will use standardised 
procedure manuals providing specific detail on their roles and data collection, plans for 
dealing with intervention fidelity issues and monitoring the delivery of the intervention. 
Participants in all groups will receive identical information and instructions regarding the 
study, except for the actual intervention.  
Data collection  
One research assistant will recruit the patients, obtain consent and collect demographic and 
clinical data. A second research assistant will deliver the intervention. Trained outcome 
assessors will collect daily data and assess the outcomes (blind to allocation). An electronic 
case record form will be developed to capture cluster level and patient level data and will be 
completed by the recruiter and/or the project manager. At the cluster level, the number of 
hospital beds, most recent HAPI rate and hospital PIP resources will be collected at baseline. 
At the individual patient level, demographic and clinical data such as gender, diagnosis, body 
mass index and risk factors for PI will be collected at baseline. This patient data will be 
collected from the medical records and the patient. The use of any other PIP interventions 
(i.e. as part of standard care) for each patient such as pressure relieving devices, special diets 
etc. will be recorded from the daily care plan, medical records or by direct observation by the 
outcome assessor. The outcome assessors will monitor and collect the same information on 
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actual PIP interventions delivered to patients in the control wards as for patients in the 
intervention wards.  
Outcome assessment 
The primary outcome is incidence of HAPI, and secondary outcomes are pressure injury 
stage, patient participation in care and health care costs. Patients will reach the trial endpoints 
of: development of a pressure injury, hospital discharge or 28 days, whichever comes first; 
transfer to another hospital or transfer to critical care requiring mechanical ventilation. The 
outcome assessors, who will be trained in skin assessment, will visually inspect the skin of all 
participants daily to determine if a PI is present, and if so, its stage. This skin assessment will 
follow international consensus guidelines for assessing PI (European Pressure Ulcer Advisory 
Panel et al., 2014). Each site will be funded for one half-time equivalent outcome assessor 
position plus weekend half-time, however due to staffing logistics (i.e. holidays, sick leave), 
3–4 outcome assessors will be trained per site and are anticipated to be used using a roster 
system. All outcome assessors will receive a full day training in outcome assessment and data 
collection. This training will include theory and practice related to full skin integrity 
assessment, PI identification and staging. All assessors will undertake a test under exam 
conditions in which they will be asked to observe high definition photographs of PIs and 
determine whether the photograph shows a PI and if so, what stage. Inter-rater reliability of 
outcome assessors will be assessed using Fleiss Kappa for multiple raters on the primary 
outcome (presence of a PI) and secondary outcome (stage of PI). Research suggests that with 
training, excellent inter-rater reliability (Kappa 1.0, i.e. 100% agreement between trained 
clinical trials nurses and their team leader) can be achieved (Nixon et al., 2005). During the 
trial, monitoring will occur, with the project manager using source data to verify the date 
entered into the electronic case report form. The outcome assessor will also collect data for 
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secondary outcomes including patients’ responses to the patient participation scale (Weingart 
et al., 2011) when patients reach the trial endpoint. This scale measures patient participation 
in inpatient care by asking seven questions around patients’ knowledge and understanding of 
medical conditions and procedures, ability to access health professionals and participate in 
decision making, and hospital experiences (Weingart et al., 2011). 
Process evaluation 
A process evaluation will be undertaken alongside the trial to explain discrepancies between 
expected and observed outcomes and provide insight into why the intervention is successful 
or not (Craig et al., 2008). A framework for designing and reporting process evaluations for 
c-RTs will be employed (Grant et al., 2013). This framework consists of a number of 
elements for evaluating processes, including recruitment and reach, intervention delivery, 
response to intervention, maintenance, context, outcomes and theory (Grant et al., 2013). In 
the process evaluation of the INTACT trial, recruitment and reach will be descriptively 
analysed using screening log data from all study sites (i.e. total number of patients screened 
vs. recruited). Intervention delivery to clusters (nurses) and individuals (patients) will be 
measured by keeping inservice logs of staff training and documenting delivery of each 
intervention component to individuals at all interventions sites. Response to the intervention 
will be explored at the cluster and individual level through nurse and patient interviews. The 
possibility of maintenance of the intervention (i.e. translation into clinical practice) will be 
explored in nurse interviews. Context will be considered at a local, state and national level 
regarding PIP care by reviewing hospital policies and procedures, state penalties and national 
standards. Unintended consequences will be assessed through any changes in policy, 
processes or routine care at each site.  
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Cost and resource use data 
A trial-based economic evaluation will be undertaken from the health system perspective to 
compare the direct healthcare costs and effects of a care bundle for PIP, relative to standard 
care. The resource utilisation data to be recorded and costed are summarised in Table 2. Costs 
related to provision of the care bundle such as time to educate patients and train nursing staff 
and costs of developing resources such as brochures, posters and DVDs will be collected for 
all trial participants, as will length of hospital stay. During a 4-week observational sub-study, 
micro-costing data will be collected by a separate research assistant, which will allow the 
calculation of direct costs to the hospital for pressure-related assessment and prevention for 
each participant across all sites. This sub-study sample is expected to represent 320 
participants (20% of the trial cohort) and will be sufficient to indicate the mean and 
distribution of costs related to implementation and other PIP strategies used for each patient. 
The sub-study will determine the number of repositioning episodes per participant, number of 
clinical staff required for repositioning, and the nurse time required per turn. Other resource 
use related to PIP such as the use of special mattresses, skincare products and incontinence 
care will also be recorded for this sub-study. These resource use data will be collected by 
directly observing the patients in the sub-study and auditing medical records. Direct costs 
(AU$ 2014) will then be allocated to each resource unit using standard costing sources. These 
data from the substudy will be used alongside intervention and length of stay data to estimate 
the total resource use and direct healthcare cost per participant for the two groups over the 
entire study period.  
Data analysis 
Blinded analyses of primary and secondary outcome measures will be undertaken at cluster 
level and patient level. Our primary hypothesis will be tested at the individual patient level 
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but adjusted for the cluster structure as per the recommendation of Cochrane methods on the 
analyses of c-RT. Generalised Estimation Equations (GEE) models, hierarchical or 
generalised mixed models and multi-level models will be used to adjust for clustering of 
patient-level data. Within each approach, simple analyses such as t-tests, Chi-square tests or 
more complex approaches such as multivariate Cox regression models will be considered. 
Both allow for the effect of the intervention on the incidence of HAPI and other secondary 
outcomes to be tested; however, only complex analyses allow adjustment for potential 
covariates. Adjustment for individual patient covariates will occur in the appropriate level of 
analyses using GEE or multi-level models.  
Cluster level analysis: The incidence rates per 1000 hospitalised days between intervention 
and standard care groups will be compared at cluster level. Estimates of the HAPI incidence 
in each group, group differences as well as the 95% CI and p values will be reported. Other 
outcomes will also be compared at the cluster levels between the intervention and control 
group. Baseline variables and other covariates will be compared between the two groups to 
ensure the intervention and control groups do not differ in their baseline characters.   
Patient Level Analysis: Patient level analyses will primarily account for the intra-cluster 
correlation, thus increasing the statistical power of the analysis. Cluster adjusted Z-tests (to 
compare the proportion between the intervention and control groups) or t-tests (to compare 
means) will be undertaken to avoid spuriously low p-value and overly narrow confidence 
levels, over-emphasizing the impact of the intervention. However, the more comprehensive 
inferences in our study will be based on the use of modelling techniques to incorporate 
patient level data adjusted for nested structure. Cox regression with robust standard error will 
be used to estimate the rate ratios given the incidence rate per person time is the main 
outcome in this study. Robust standard error accounts for the correlation outcome within each 
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hospital. Cox regression will also adjust for a number of pre-specified covariates in 
comparing the incidence of HAPI between the intervention and standard care group. These 
modelling techniques allow the direct correlation within clusters to be modelled explicitly, 
and many potential confounding factors will be included in the model when comparing the 
effect of the intervention. Such models will be developed for primary and secondary 
outcomes. We will use STATA for the analyses of our data. An intention to treat analysis will 
be used but we will also undertake a per protocol analysis to elucidate differences in 
outcomes depending on the intended vs. actual intervention received. 
Cost-effectiveness Analysis: Detailed within-trial resource utilisation and costs will be used to 
undertake a stepped economic evaluation and estimate (i) the comparative per patient HAPI 
related healthcare prevention costs for each group, and (ii) the comparative incremental cost 
of preventing an additional case of HAPI. As the duration of the trial is less than one year, 
discounting will not be applied to costs or benefits. Hierarchical modelling approaches and 
cluster-adjusted non-parametric bootstrapping techniques will be employed to compare mean 
difference in the total costs between groups, and to estimate a confidence interval around the 
mean (Bachmann et al., 2007). In addition, a cost-effectiveness analysis will be undertaken 
based on the primary outcome measure (incidence of HAPI), to estimate the incremental cost 
per additional person remaining free from PI.  
 DISCUSSION 
This study will provide important information on the effectiveness of a patient-centred PIP 
care bundle to reduce the incidence and severity of HAPI in at-risk patients, improve patient 
participation in their care and reduce associated health care costs. To our knowledge, this is 
the first randomised study to incorporate a number of recognised PIP strategies into a care 
bundle with a focus on patient engagement and nurse-patient partnership. This is a novel 
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approach to a significant clinical problem. It is multifaceted, patient-focused and expected to 
maximise effectiveness and sustainability. 
PIP is of high importance considering the significant patient consequences and economic 
burden to hospitals. As noted by an international Expert Wound Care Advisory Panel, PI 
research lags behind that in other areas of medicine and very few RCTs have been conducted 
(Armstrong et al., 2008). Whilst recent systematic reviews show promising evidence around 
care bundles (i.e. a set of evidence based practices) for PIP (Soban et al., 2011, Sullivan and 
Schoelles, 2013), it has been suggested that further research is needed to better understand 
implementation, mechanisms (or causal pathways) and the role of context in intervention 
success or failure (Soban et al., 2011). This proposed c-RT will be cutting edge. If it confirms 
the utility of a patient centred PIP care bundle, it could change practice worldwide.  
This study has a number of strengths, including its robust design. Cluster randomisation (i.e. 
by hospital) will ensure there is no contamination between study groups. Thorough training 
of interventionists and data collectors will optimise fidelity and reliability. Whilst blinding of 
patients is not possible due to the need for informed consent, blinding of data collectors and 
nurses to study design and hypotheses, and blinding of outcome assessors and data analysts to 
group allocation will minimise bias. The study also has a strong theoretical base. Care 
bundles have been shown to improve patient outcomes and are based on core practice 
guidelines (Institute for Healthcare Improvement, 2014, Rello et al., 2011). Patient 
participation in their health care results in improved outcomes and responses to interventions, 
and is promoted by leading healthcare organisations worldwide (Australian Commission on 
Safety and Quality in Health Care, 2011, Joint Commission on Accreditation in Healthcare 
Organizations, 2006, World Health Organisation, 2007). The inclusion of an economic sub-
study will strengthen the impact of the findings by providing meaningful cost-analysis data, 
22 
 
and may inform recommendations on the adoption of the intervention for PIP in clinical 
practice. Finally, the inclusion of a process evaluation will provide important information on 
implementation and give insight into why the intervention is successful or not and how it may 
be optimised.  
Challenges in this trial may include: (1) reaching recruitment targets, but we plan to increase 
the number of wards participating at each site if required; (2) when patients are unexpectedly 
discharged, resulting in missing outcome data, although we have considered hospital 
discharge practice in timing outcome assessments; (3) ensuring the blinding of research 
assistants (including outcome assessors) to study site group allocation, but we will assess 
their perception of group allocation; and (4) avoiding selection bias, however this will be 
addressed by using a ward randomisation schedule and recruiting consecutive patients 
according to the schedule.  
The results of this study will be presented at local hospital, patient safety and university fora, 
and a press release will be prepared. Abstracts will be submitted to major international 
meetings such as patient safety, nursing and medicine and published in high-ranking health 
services and medical/nursing journals. The results will have international application and 
implications for clinical practice and nursing education. If successful, testing of the 
intervention internationally would be indicated, and it should be rapidly adopted and cited in 
Australian core practice guidelines.  
Trial status 
At the time of manuscript submission, data collection has commenced at all study sites. 
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Figure 1: Anticipated participant flow through study 
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Table 1: Content of patient education 
Message Summary of content 
1. Keep 
moving 
• Change position whilst in bed or in a chair 
• Use pillows for support or ask staff for help when changing position 
• Keep active by going for walks if possible 
2. Look after 
your skin 
• Advise staff of pain, tenderness, redness or blistering over bony areas 
• Keep skin, clothes and bedding clean and dry 
• Use moisturising lotion and mild cleanser or moisturising soap to 
prevent drying out of skin 
• Special equipment (i.e. air mattresses, pressure relieving cushions, 
booties) may be used to reduce pressure 
3. Eat a 
healthy diet 
• Good nutrition is important for skin protection and wound healing 
• Ensure good protein sources (examples given) for skin maintenance 
• Drink plenty of fluids for hydration 
• Consult with a dietitian or nutritionist 
• Take nutrition supplements as prescribed 
Note: The intervention materials include a detailed brochure, which will be explained to patients by 
interventionists; a five minute DVD; and a poster, summarising the three key messages. 
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Table 2: Summary of resource data collection and costing methods 
Resource to be measured Data collection and costing method Source for unit cost 
PIPCB Intervention 
Materials including poster, 
brochure, DVD 
Fixed cost, averaged across all trial 
participants 
Commercial provider 
Staff time for patient education 
and nurse training 
Recorded by RA for all patients in trial 
and estimated from nurse training 
sessions 
Staff salary hourly rates 
(including on-costs) 
PIP strategies 
Clinical staff time for turning Observational sub-study: number of 
nurses per turn, turns per patient and 
time per turn observed, confirmed with 
patient,  and recorded by RA 
Staff salary hourly rates 
(including on-costs) 
PIP products (including 
mattresses, wedges, rings and 
cushions; skincare products; 
incontinence care; dressings for 
PIP) 
Observational sub-study: observed, 
confirmed with patient,  and recorded 
by RA 
Hospital cost centre 
Dietitian consult for the purpose 
of PIP 
Observational sub-study: patient notes, 
confirmed with patient,  and recorded 
by RA 
Staff salary hourly rates 
(including on-costs) 
Hospital length of stay Length of stay recorded by RA for all 
patients in trial 
Independent Hospital 
Pricing Authority (2014) 
 
 
